Clinical Trial Update: A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Esketamine nasal spray as monotherapy in adults with treatment-resistant depression has completed, with results posted on 2025-03-04.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Treatment-resistant Depression

Drugs mentioned

• SPRAVATO (ESKETAMINE HYDROCHLORIDE)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Depressive Disorder, Treatment-Resistant | Phase 4 | Status: COMPLETED | Results posted: 2025-03-04